openPR Logo
Press release

Roche, AstraZeneca Market Share in North America and Europe PEGylated Drugs Market|Key Players: Pfizer, Amgen, Biogen, Novo Nordisk

02-11-2019 07:30 PM CET | Health & Medicine

Press release from: Global Market Insights Inc.

North America and Europe PEGylated Drugs Market

North America and Europe PEGylated Drugs Market

Global North America and Europe PEGylated Drugs Market set to exceed USD 10.5 billion by 2024; according to a new research report by Global Market Insights.

Increasing R&D investment of biotechnology & pharmaceutical companies to develop enhanced PEGylated drugs for treatment of various chronic diseases along with rising occurrence of chronic ailments in developed regions will propel PEGylated drugs market growth over the forecast period. Major advancements in biologics sector including advances in drug antibody conjugates, and immunotherapies will positively impact market growth.

Moreover, rising incidences of chronic ailments and increasing death rates associated with cancer in Canada will propel industry growth. However, the side-effects associated with pegylated drugs along with drug failure will impede PEGylated drugs market growth over the forecast timeframe.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Roche
• AstraZeneca
• Pfizer
• Amgen
• Biogen
• Novo Nordisk
• UCB
• Merck KGaA

Cancer segment held over 60% of the overall market share in 2017 due to growing prevalence of the disease creating a demand for the development of effective drugs. Benefits offered by PEGylated drugs such as reduced proteolytic degradation along with minimized immunogenicity leading to enhanced therapeutic efficacy will propel market growth. Increasing areas of applications as well as rising adoption of PEGylated drugs to treat various types of cancer will stimulate business growth. Hepatitis segment size was USD 156 million in 2017 and is anticipated to follow a declining trend over the forecast period. However, increasing focus of industry players to develop pegylated drugs used for the treatment of such chronic conditions will contribute to market growth. For instance, launch of Pegasys drug used for treating Hepatitis C in adult patients will fuel market growth.

To understand the implications of the cancer segment in defining the North America and Europe PEGylated drugs market, in 2015 about 1.3 million or 26% of all deaths in Europe resulted from cancer, making it the second biggest cause of fatalities in the EU. The upsurge in cigarette smoking and pollution along with unhealthy dietary consumption among EU population is expected to increase the frequency cancer and other chronic diseases. Consequently, the advantages of PEGylated drugs in improving treatments has inspired a number of companies in the region to develop bio-conjugated drugs, strengthening the North America and Europe PEGylated drugs industry.

Elaborating on the significance of North America and Europe PEGylated drugs market, a slew of PEGylated drug delivery systems such as Neulasta, Onivyde and PEG intron are employed in various cancer treatments, with additional drugs in the pipeline or pending approvals. For instance, the U.S. Food and Drug Administration (FDA) accepted a biologics license application from Shire PLC, a biotech leader in rare diseases, for Calaspargase Pegol (Cal-PEG) as a component of antineoplastic combination therapy for acute lymphoblastic leukemia (ALL) patients. The development is based on Shire’s research and experience with ONCASPAR (pegaspargase), a first-line treatment for ALL approved in the U.S. According to reports on the efficiency and safety of Cal-PEG, if approved it will permit availability of treatments that have a prolonged shelf life beyond the current PEGylated asparaginase treatment.

The advent of PEGylation to increase the power and life of drug induced therapies can be justified by explaining the impact of acute lymphoblastic leukemia (ALL). ALL is technically a cancer of the white blood cells, which leads to excess lymphoblasts in the blood, bone marrow and other locations in the body. The American Cancer Society estimates that the risk of developing the disease is highest among children below 5 years of age, which declines gradually by the mid-20s and then arises again after the age of 50. Further, ALL accounts for close to 75% of the overall leukemia cases in U.S. children and up to 78% for the children in Europe. As such, the obligation to produce potent medicines for combination therapeutic treatments has driven the North America and Europe PEGylated drugs industry.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511

North America & Europe PEGylated Drugs Market by Disease Indication
o Cancer
o Hepatitis
o Multiple sclerosis
o Gastrointestinal disorders
North America & Europe PEGylated Drugs Market by Type
o Monoclonal antibodies (mAbs)
o Colony stimulating factors
o Interferons

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Roche, AstraZeneca Market Share in North America and Europe PEGylated Drugs Market|Key Players: Pfizer, Amgen, Biogen, Novo Nordisk here

News-ID: 1578209 • Views:

More Releases from Global Market Insights Inc.

Latest Research Report On Agricultural Adjuvants Market 2021. Major Players Included – Dow Dupont Inc., BASF SE, Clariant AG & More
Latest Research Report On Agricultural Adjuvants Market 2021. Major Players Incl …
The agricultural adjuvants market is expected to observe noteworthy growth on account of increasing demand for high-quality crops. Adjuvants commonly act as an additive in pesticides that increase its effectiveness and smoothen its mixing application. The demand for plant protection products in countries like Bangladesh, India, and Vietnam has surged considerably in recent years. Ever-increasing population across developing economies has forced farmers to produce large quantities of high-quality yields. Citing
U.S. Minoxidil Market 2021 Growth Opportunities and Competitive Landscape 2027 - Walmart, Costco Wholesale Corporation, LGM Pharma
U.S. Minoxidil Market 2021 Growth Opportunities and Competitive Landscape 2027 - …
The U.S. minoxidil industry has been impacted by the COVID-19 pandemic in the form of increased stress amid job losses and health issues, creating rising incidences of hair fall and associated problems. The industry is expected to gain commendable proceeds on account of an upsurge in research studies concerned with the effectiveness of minoxidil. Citing one such instance, in January 2021, a study published in the Dermatologic Therapy supported the efficacy
Global Sulfosuccinate Market 2021 Future Growth With Technology and Current Trends to 2024 | MFG Chemicals, Huntsman Corporation, and Stepan Company
Global Sulfosuccinate Market 2021 Future Growth With Technology and Current Tren …
Owing to these factors, estimates have revealed that the global sulfosuccinate market size will exceed USD 475.7 million in annual estimation by 2024. Increasing adoption of high-performance materials that meet application-specific requirements across various industries, including pharmaceuticals will stimulate the need for sulfosuccinate compounds. The surging disposable incomes of consumers mainly across the developing nations have also fueled their spending capacities on household and personal care. Sulfosuccinates are mainly a mild type
By 2026, Graphene Market will register over 35% CAGR | Applied Nanotech, Inc, an …
The global Graphene Market is slated to gain significant momentum over the forthcoming years, as a result of the growing product consumption in the electronics sector, particularly in developing countries. This high consumption can be attributed to its superior qualities such as high electrical conductivity, durability, and toughness. Request a sample of this research report @ https://www.gminsights.com/request-sample/detail/233 Top Key Players in The Market are: Graphenea S.A., Applied Graphene Materials plc, ACS

All 5 Releases


More Releases for PEG

Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever. PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications. "Biopharma PEG is committed to delivering high-purity multi-arm
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,